CrystalsFirst

About:

Overcoming current limitations of small molecule drug discovery using proprietary structural biology technology and generative AI.

Website: https://www.crystalsfirst.com/

Top Investors: VentureOut, EXIST, MassChallenge, Hessen Kapital I

Description:

CrystalsFirst's MAGNET platform overcomes current limitations of small molecule drug discovery. The integration of high-performance structural biology detects molecular magnets and generative AI/Machine Learning identifies novel molecules and druggable binding pockets for difficult targets. Our MAGNET Platform is a unique and powerful approach to unlock chemical matter. It integrates the “crystal structure first” strategy, large-scale computational modelling, generative AI and medicinal chemistry. Starting with crystal structures as the first step in drug discovery, we also gain valuable insights into target interactions, enabling rational design from the beginning. Building block chemistry provides rapid access to diverse chemical scaffolds, facilitating hit expansion, scaffold hopping, and efficient compound generation. Computational modelling and machine learning aid in predicting compound properties and optimizing lead candidates. The synergistic combination of these elements in the MAGNET Platform accelerates the discovery process and increases the likelihood of finding innovative and effective therapeutic compounds.

Total Funding Amount:

757000 EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Marburg, Hessen, Germany

Founded Date:

2018-02-28

Contact Email:

contact(AT)crystalsfirst.com

Founders:

Serghei Glinca, Stefan Merkl

Number of Employees:

11-50

Last Funding Date:

2022-08-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai